XPO1 and neoplasm: In NPM1/FLT3 co-mutant AML, combining XPO1 inhibitors with FLT3 inhibitors (e.g., gilteritinib) further targets immune evasion: FLT3 inhibition reduces FLT3 ligand-mediated suppression of NK cells, while XPO1 blockade restores p53/FOXO-driven immune activation, creating a synergistic anti-tumor immune response (Daver and Craddock, 2024).